Prof Dr Ryszard Pluta | Neuroscience | Best Researcher Award

Posted on by sciencefather

Prof Dr Ryszard Pluta | Neuroscience | Best Researcher Award

MD.,PhD at  Medical University of Lublin , Poland

Dr. Ryszard Pluta is a distinguished neurologist and neuroscientist, with a medical degree from the Medical Academy in Lublin (1977) and a Ph.D. from the Polish Academy of Sciences (1983). He has served as a Professor at the Mossakowski Medical Research Institute and held prestigious postdoctoral fellowships at the NIH and NYS Institute for Basic Research. A recognized expert in brain ischemia and Alzheimer’s disease, Dr. Pluta has published extensively, including multiple influential books on the subject. He is a recipient of numerous awards and is an active member of several professional societies. His significant contributions to understanding the links between ischemia and Alzheimer’s have established him as a leading figure in neuropathology.

Profile:

Scopus 

Education 🎓

Ryszard Pluta earned his medical degree from the Medical Academy in Lublin (1971-1977) and attended Humboldt University in Berlin (1975) and the University of Cologne (1976). He completed his Ph.D. at the Polish Academy of Sciences in Warsaw (1983). He became an Associated Professor in 1992 and a full Professor in 2004 at the Mossakowski Medical Research Institute, Polish Academy of Sciences.

Work Experience 💼

Dr. Pluta has held prestigious positions, including postdoctoral fellowships at the NIH in Bethesda, USA (1986-1988), and the NYS Institute for Basic Research in New York (1988-1989). He has been a Visiting Professor at several renowned institutions, including the Max-Planck Institute for Neurological Research and Charles University in Prague.

Skills 🧠

With extensive expertise in neuropathology and neurochemistry, Dr. Pluta specializes in brain ischemia and Alzheimer’s disease research. His skills encompass project management, collaboration with international research teams, and contributions to clinical studies in the field of neuroscience.

Awards and Honors 🏆

Dr. Pluta has received numerous accolades, including recognition from the Polish Association of Neuropathologists (1980, 1986) and the Polish Academy of Sciences (1982, 1989, 1992). He was also honored by the International Brain Research Organization (1997) and the Alzheimer’s Association in Chicago (1998).

Membership 🤝

He is an active member of various professional organizations, including the Polish Association of Neuropathologists and the International Society of Neuropathology. Dr. Pluta is recognized among the World’s Top 2% scientists by Stanford University.

Teaching Experience 📚

Dr. Pluta has contributed to the academic community through teaching positions at various universities, where he has shared his knowledge and expertise in neuropathology and neuroscience with students and researchers.

Research Focus 🔬

His research focuses on brain ischemia, its relationship with Alzheimer’s disease, and associated neuropathological changes. He has made significant contributions, such as the documentation of identical changes in ischemic brains and those affected by Alzheimer’s, and the exploration of potential therapeutic approaches involving β-amyloid peptide.

 

Publications:

  • Alpha-, Beta-, and Gamma-Secretase, Amyloid Precursor Protein, and Tau Protein Genes in the Hippocampal CA3 Subfield in an Ischemic Model of Alzheimer’s Disease with Survival up to 2 Years
    • Year: 2024
    • Journal: Journal of Alzheimer’s Disease
  • Trans- and Cis-Phosphorylated Tau Protein: New Pieces of the Puzzle in the Development of Neurofibrillary Tangles in Post-Ischemic Brain Neurodegeneration of the Alzheimer’s Disease-like Type
    • Year: 2024
    • Journal: International Journal of Molecular Sciences
  • A Look at the Etiology of Alzheimer’s Disease based on the Brain Ischemia Model
    • Year: 2024
    • Journal: Current Alzheimer Research
  • Apoptosis, Autophagy, and Mitophagy Genes in the CA3 Area in an Ischemic Model of Alzheimer’s Disease with 2-Year Survival
    • Year: 2024
    • Journal: Journal of Alzheimer’s Disease
  • Ischemia-Reperfusion Programming of Alzheimer’s Disease-Related Genes—A New Perspective on Brain Neurodegeneration after Cardiac Arrest
    • Year: 2024
    • Journal: International Journal of Molecular Sciences
  • LRP1 and RAGE Genes Transporting Amyloid and Tau Protein in the Hippocampal CA3 Area in an Ischemic Model of Alzheimer’s Disease with 2-Year Survival
    • Year: 2023
    • Journal: Cells
  • The Dual Role of Autophagy in Postischemic Brain Neurodegeneration of Alzheimer’s Disease Proteinopathy
    • Year: 2023
    • Journal: International Journal of Molecular Sciences
  • Preservation of Biomarkers Associated with Alzheimer’s Disease (Amyloid Peptides 1-38, 1-40, 1-42, Tau Protein, Beclin 1) in the Blood of Neonates after Perinatal Asphyxia
    • Year: 2023
    • Journal: International Journal of Molecular Sciences
  • Apitherapy in Post-Ischemic Brain Neurodegeneration of Alzheimer’s Disease Proteinopathy: Focus on Honey and Its Flavonoids and Phenolic Acids
    • Year: 2023
    • Journal: Molecules
  • Post-Ischemic Permeability of the Blood–Brain Barrier to Amyloid and Platelets as a Factor in the Maturation of Alzheimer’s Disease-Type Brain Neurodegeneration
    • Year: 2023
    • Journal: International Journal of Molecular Sciences

Dr. Amira Boseila | Neuroscience| Best Researcher Award

Posted on by sciencefather

Dr. Amira Boseila | Neuroscience| Best Researcher Award🏆


Lecturer at Sinai University,Egypt🎓

Dr. Amira Abdel Halim Hamada Boseila is a full-time lecturer in Pharmaceutical Sciences at Sinai University, Egypt, where she teaches advanced courses in drug delivery systems and pharmaceutics. She also serves as a post-doctoral researcher at the National Organization for Drug Control and Research (NODCAR) and the Egyptian Drug Authority. With a PhD from Cairo University, her research focuses on nanomedicine, drug targeting, and innovative drug delivery systems. Dr. Boseila has contributed to several impactful publications and is actively involved in various research projects aimed at enhancing therapeutic strategies.

 

Professional Profile 

🎓 Education

Dr. Amira Abdel Halim Hamada Boseila holds a Doctor of Philosophy in Pharmaceutical Sciences from the Faculty of Pharmacy at Cairo University, awarded in February 2020, with a thesis focused on the utility of nanocarriers for targeted delivery of an antiviral drug to the liver. She also earned a Master of Pharmaceutical Sciences from Cairo University in December 2013, where her thesis was centered on the formulation and evaluation of a modified nasal drug delivery system for the antiemetic drug ondansetron. Additionally, she completed a Total Quality Management Diploma at the American University of Cairo in 2009, further enhancing her expertise in quality control management. Her academic journey began with a Bachelor of Pharmaceutical Sciences from Cairo University, graduating in May 2007 with a grade of very good. She attended La Rose De Lisieux/Language School in Dokkie, where she completed her high school education with a focus on science from September 1990 to June 2002.

 

🏢 Work Experience

Full-time lecturer at the Faculty of Pharmacy, Sinai University since September 2022, and post-doctoral researcher at NODCAR and the Egyptian Drug Authority since July 2020. Previously held positions as lead quality control specialist and head of the Comparative Dissolution Unit. Guest lecturer on drug targeting at Ain Shams University since October 2020

🧬 Skills

Expertise in novel drug delivery systems, nanomedicine, drug targeting, pharmacokinetics, comparative dissolution studies, and quality by design

Awards and Honors 🏆

Recognized for contributions to pharmaceutical research through impactful publications and ongoing collaborations with prestigious institutions, including funded research projects from the University of Hail and Misr El Kheir Foundation

🔬 Research Focus

Dedicated to advancing nanomedicine and innovative drug delivery systems, with a focus on developing targeted therapies and modified release dosage forms. Actively involved in projects aimed at repurposing anti-inflammatory agents and formulating virucidal throat sprays

📚 Publication 

  • Impact of Lyophilized Milk Kefir-Based Self-Nanoemulsifying System on Cognitive Enhancement via the Microbiota–Gut–Brain Axis
    Author: Amira Boseila
    Citation: MDPI, 2023
  • Throat Spray Formulated with Virucidal Pharmaceutical Excipients as an Effective Early Prophylactic or Treatment Strategy Against Pharyngitis Post-Exposure to SARS-CoV-2
    Author: Amira Boseila
    Citation: ScienceDirect, 2024
  • Antidepressive and Cardioprotective Effects of Self-Nanoemulsifying Self-Nanosuspension Loaded with Hypericum Perforatum on Post-Myocardial Infarction Depression in Rats
    Author: Amira Boseila
    Citation: Springer, 2022
  • Recent Advances in Adsorptive Nanocomposite Membranes for Heavy Metals Ion Removal from Contaminated Water: A Comprehensive Review
    Author: Amira Boseila
    Citation: MDPI, 2023
  • Iron Oxide Nanoparticles-Plant Insignia Synthesis with Favorable Biomedical Activities and Less Toxicity, in the “Era of the-Green”: A Systematic Review
    Author: Amira Boseila
    Citation: NIH, 2023
  • In Silico and In Vitro Studies for Benzimidazole Anthelmintics Repurposing as VEGFR-2 Antagonists: Novel Mebendazole-Loaded Mixed Micelles with Enhanced Dissolution and Anticancer Activity
    Author: Amira Boseila
    Citation: PubMed, 2023
  • Superiority of DEAE-Dx-Stabilized Cationic Bile-Based Vesicles over Conventional Vesicles for Enhanced Hepatic Delivery of Daclatasvir
    Author: Amira Boseila
    Citation: Molecular Pharmaceutics, 2023
  • Design of Bile-Based Vesicles (BBVs) for Hepatocytes Specific Delivery of Daclatasvir: Comparison of Ex-Vivo Transenterocytic Transport, In-Vitro Protein Adsorption Resistance, and HepG2 Cellular Uptake of Charged and β-Sitosterol Decorated Vesicles
    Author: Amira Boseila
    Citation: PubMed, 2023
  • Preparation and Characterization of Thermosensitive Mucoadhesive In-Situ Gels for Nasal Delivery of Ondansetron Hydrochloride
    Authors: A.A. Boseila, A.Y. Abdel-Reheem, G. Abdelbary
    Citation: Al-Azhar Journal of Pharmaceutical Sciences, 2014

 

Dr NISHI PATEL | Neuroscience | Best Researcher Award

Posted on by sciencefather

Dr NISHI PATEL | Neuroscience | Best Researcher Award   🏆

Research Scholar at Bhagwan Mahavir University, Surat , India🎓

Dr. Nishi Jayesh Patel is a dedicated research scholar at Bhagwan Mahavir University, specializing in the study of Parkinson’s Disease 🧠. With over four years of significant contributions in this field, she has become an expert in neurodegenerative disorders, particularly focusing on microbiology and probiotics. Dr. Patel has published research on the relationship between gut microflora and Parkinson’s, exploring innovative treatments such as in-vitro probiotic formulations. She is also a member of the Parkinson’s Foundation, continually striving to advance knowledge and treatment for the disease.

 

Professional Profile 

  • Google Scholar 

Education 🎓

Dr. Patel holds advanced degrees in microbiology and neurological sciences, fueling her passion for neurodegenerative disease research. Her academic excellence and thorough understanding of Parkinson’s Disease enable her to make meaningful strides in the field.

Work Experience 🏢

Apart from her research work, Dr. Patel is a seasoned subject matter expert and has contributed significantly to academic assessment by setting papers for national and international entrance exams. Her work in this area has helped shape the academic landscape and ensure high standards for future medical professionals.

Awards and Honors 🏆

While specific awards are not mentioned, Dr. Patel’s numerous professional contributions, including her membership in the Parkinson’s Foundation, speak to her dedication and excellence in the field of medical research.

Research Focus 🔍

Dr. Patel’s core research focuses on probiotics and their role in neurological disorders. She has identified six bacterial strains that are potential candidates for therapeutic use in Parkinson’s Disease, with promising results in balancing GABA collapse, improving drug bioavailability, and controlling disease progression. These isolates show potential in controlling mood, immunity, and digestion, positively influencing patients’ well-being.

 

 

Publications : 

  • Evaluating Probiotic Properties of Gut Microflora for Gut Modulation as an Adjuvant Therapy for Parkinson’s Disease
    Authors: NJ Patel, M Hajoori
    Journal: Journal of Future Foods
    Year: 2025
    Volume: 5
    Issue: 3
    Pages: 304-316
  • Isolation, Characterisation, and Screening of Gut Bacteria for Essential Probiotic Characteristics
    Authors: DPD Nishi Jayesh Patel, Dr. Murtaza Hajoori
    Journal: European Journal of Biomedical and Pharmaceutical Sciences
    Year: 2023
    Volume: 10
    Issue: 11
    Pages: 176-179
  • Comparative Formulation and Evaluation of Probiotic Products Utilizing Different Bacterial Strains: A Comprehensive Study
    Authors: DPD Nishi Jayesh Patel, Dr. Murtaza Hajoori
    Journal: Biological Forum – An International Journal
    Year: 2023
    Volume: 15
    Issue: 5
    Pages: 1747-1752
  • Psychobiotics: The Next Generation Adjuvant Therapy and Its Revolutionary Contribution in Treatment for Parkinson’s Disease
    Authors: DPD Nishi Jayesh Patel, Dr. Murtaza Hajoori
    Journal: Futuristic Trends in Medical Sciences
    Year: 2022
    Book: 21, Part 1
    Pages: 1-15
  • Bioremediation of Surfactants by Bacteria Isolated from Spume Used to Scavenge Surfactants Along with Dyes in Washing Textile Effluents
    Author: DRD Nishi Jayesh Patel
    Journal: JETIR Research Journal
    Year: 2020
    Volume: 7
    Issue: 6
    Pages: 1147-1153

 

Prof Dr Katsunori Nonogaki | Neuroscience | Best Researcher Award

Posted on by sciencefather

Prof Dr Katsunori Nonogaki | Neuroscience | Best Researcher Award 🏆

Division of Diabetes and Nutrition at RARiS, Tohoku University, Japan
🎓

Dr. Katsunori Nonogaki is a distinguished professor and clinical specialist in diabetes and internal medicine, holding extensive expertise in lifestyle medicine and diabetes research. He obtained his MD in Japan in 1987, followed by a PhD from Nagoya University Graduate School of Medicine in 1993. His postdoctoral training included positions at UCSF and The Scripps Research Institute, where he focused on metabolism and neuropharmacology. Dr. Nonogaki has held key academic roles at prestigious institutions, including the University of Tokyo and Tohoku University, where he has been a professor since 2008.

Professional Profile 

📚 Work Experience & Teaching

Dr. Nonogaki has a long-standing academic career, beginning as a lecturer at the University of Tokyo before joining Tohoku University in various professorial roles. His teaching experience spans undergraduate to postgraduate levels, where he mentors future leaders in diabetes research and metabolic health.

🎖️ Skills, Awards, and Honors

Dr. Nonogaki is highly skilled in molecular nutrition, metabolic diseases, and translational research. He has served as the Chief of the Laboratory of Molecular Nutrition and is recognized for his contributions to diabetes research, earning several awards in this domain. He has also made impactful contributions to scientific literature, serving on the editorial boards of key journals such as Frontiers in Endocrinology and Diabetes Research and Clinical Practice.

🌐 Memberships & Professional Involvement

His professional involvement extends to numerous editorial roles, including Topic Editor and Associate Editor in leading journals. Dr. Nonogaki is a highly regarded member of the international diabetes research community, where he actively contributes to advancements in metabolic health and diabetes management.

Research Focus

Xiaofeng’s research is centered on entrepreneurial behavior, project selection, and risk assessment. He has proposed a three-stage theory for project selection and developed a dynamic measurement model for entrepreneurial risks. His work has practical implications, particularly in the evaluation of risks in family farms and entrepreneurship education. His 65 published journal articles and various patents further underscore his contributions to the field.

 

Publications : 

“The GLP-1 Receptor Agonist Liraglutide Decreases Primary Bile Acids and Serotonin in the Colon Independently of Feeding in Mice”
Year: 2024
Journal: International Journal of Molecular Sciences

Dr Alexandros Kanellopoulos | Neuroscience | Best Researcher Award

Posted on by sciencefather

Dr Alexandros Kanellopoulos Neuroscience | Best ResearcherAward  🏆

Principal Scientist of Cognitive Health at DSM-Firmenich, RD Innovation
Switzerland🎓

Alexandros Kanellopoulos is a seasoned Innovation Leader, Principal Scientist, and Clinical Director with over 20 years of expertise in Neuroscience, Metabolism, Early Life Nutrition (ELN), and Medical Nutrition. He has successfully led multidisciplinary teams, pioneered product innovations, and authored more than 20 high-impact publications. With 7 patents to his name, Alexandros excels in transforming scientific research into tangible solutions that meet market needs.

Professional Profile 

Education

Alexandros Kanellopoulos holds a Ph.D. in Neuroscience from Kapodistrian University, Greece (2008-2013), where his research focused on neurodevelopmental disorders. Prior to this, he completed his M.Sc. in Molecular Medicine (Neuroscience) at the same university (2005-2007), gaining advanced expertise in neuroscience and molecular biology. His academic foundation was established with a B.Sc. in Molecular Biology and Genetics from Dimocritus University of Thrace, Greece (2000-2005), where he developed a strong background in genetics and molecular biology.

Work Experience

In his current role as Global Principal Scientist & Clinical Director at DSM-Firmenich (2023-Present), Alexandros oversees scientific activities, driving innovation in dietary supplements and medical nutrition. Prior to this, he worked as an R&D Innovation Scientist and Project Manager at Nestle SA (2022-2023), leading the development of brain health products for Early Life Nutrition. In 2023, he also held the position of Medical, Scientific & Regulatory Affairs Manager at Nestle Nutrition, focusing on market communication and regulatory compliance. Alexandros previously served as Group Leader, Early Life Brain Metabolism at the University of Lausanne (2020-2022) and as Senior Scientist in Early Life Neuroscience (2016-2020), where he pioneered research in neurodevelopmental disorders.

Skills 

Alexandros is highly skilled in Innovation & Product Development, leading projects from concept to market. He is an expert in Clinical Research & Protocol Design, managing complex preclinical and clinical trials. His ability to lead multidisciplinary teams and drive Cross-functional Collaboration is complemented by his talent for Stakeholder Engagement & Market Alignment, ensuring alignment between research innovations and market needs. His Strategic Thinking, Problem-solving, and Emotional Intelligence are key to his success in high-impact research and business projects.

Awards & Honors

Throughout his career, Alexandros has earned more than 15 research awards, securing CHF 2.5 million in research funding. He has been awarded 7 patents as an inventor, reflecting his contributions to innovation in neuroscience and nutrition. In addition, he has delivered over 40 invited presentations at international conferences, establishing himself as a respected thought leader in his field.

 Membership 

Alexandros contributes to the scientific community as a Reviewer for leading neuroscience journals and serves as an Editor in scientific publications, ensuring the dissemination of high-quality research.

Teaching Experience

Alexandros is also an experienced educator, having delivered lectures in Neuroscience and Medical Sciences at the University of Lausanne and Kapodistrian University, Athens. In his academic roles, he has mentored over 20 junior scientists, fostering the next generation of researchers and innovators.

Research Focus

Alexandros’ research centers on Early Life Nutrition and its role in brain development. He is particularly focused on Neurodevelopmental Disorders such as Autism and Fragile X Syndrome. His work on Brain Energy Metabolism and Mitochondrial Function provides insights into neurotransmission and social behavior. Alexandros has also designed Preclinical and Clinical Research aimed at developing nutritional solutions to address these complex medical challenges.

Publications : 

  • Activation of the 5-HT1A Receptor by Eltoprazine Restores Mitochondrial and Motor Deficits in a Drosophila Model of Fragile X Syndrome
    🧠 International Journal of Molecular Sciences – 2024
    DOI: 10.3390/ijms25168787
  • Aralar Sequesters GABA into Hyperactive Mitochondria, Causing Social Behavior Deficits
    🧬 Cell – 2020
    DOI: 10.1016/j.cell.2020.02.044
  • Conserved Tao Kinase Activity Regulates Dendritic Arborization, Cytoskeletal Dynamics, and Sensory Function in Drosophila
    🔬 The Journal of Neuroscience – 2020
    DOI: 10.1523/jneurosci.1846-19.2020
  • Domain-Specific Cognitive Impairments in Humans and Flies With Reduced CYFIP1 Dosage
    🧩 Biological Psychiatry – 2019
    DOI: 10.1016/j.biopsych.2019.04.008
  • SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the Synapse
    🧠 Neuron – 2019
    DOI: 10.1016/j.neuron.2019.05.002
  • Mitochondrial Dysfunction in Autism Spectrum Disorder: Clinical Features and Perspectives
    🧠 Current Opinion in Neurobiology – 2017
    DOI: 10.1016/j.conb.2017.05.018
  • Autism Spectrum Disorders: Translating Human Deficits into Mouse Behavior
    🐁 Neurobiology of Learning and Memory – 2015
    DOI: 10.1016/j.nlm.2015.07.013
  • Learning and Behavioral Deficits Associated with the Absence of the Fragile X Mental Retardation Protein: What a Fly and Mouse Model Can Teach Us
    🧠 Learning & Memory (Cold Spring Harbor, N.Y.) – 2014
    DOI: 10.1101/lm.035956.114
  • Learning and Memory Deficits Resulting from Reduction of the Fragile X Mental Retardation Protein: A Metabotropic Glutamate Receptor-Mediated Inhibition of cAMP Signaling in Drosophila
    🧠 The Journal of Neuroscience – 2012
    DOI: 10.1523/JNEUROSCI.1347-12.2012
  • Selective Serotonin Reuptake Inhibitors for the Treatment of Hypersensitive Esophagus: A Randomized, Double-blind, Placebo-controlled Study
    💊 The American Journal of Gastroenterology – 2011
    DOI: 10.1038/ajg.2011.179

Dr Andreu Massot Tarrús | Neuroscience | Best Researcher Award

Posted on by sciencefather

Dr Andreu Massot Tarrús | Neuroscience | Best Researcher Award 🏆

Neurologist at Hospital Universitari Mútua Terrassa, Spain🎓

Andreu Massot Tarrús, MD, PhD, is a highly accomplished neurologist and epileptologist with over 20 years of experience. He earned his Medical Doctorate from the Universitat Autònoma de Barcelona in 2003 and later completed a PhD Cum Laude in Medicine, focusing on intracranial atherostenosis. He has held senior neurology positions at prestigious hospitals in Spain, including Hospital Universitari Vall d’Hebron, Jiménez Díaz Foundation, and Hospital Universitari Mútua Terrassa, where he currently serves. Dr. Massot Tarrús has specialized expertise in epilepsy, EEG, and cerebrovascular diseases and has completed advanced fellowships in Canada and the UK.

Professional Profile 

Education

Andreu Massot Tarrús earned his Medical Doctorate in August 2003 from the Universitat Autònoma de Barcelona. He went on to complete his Neurology specialization in May 2009 at the Hospital Universitari Vall d’Hebron, Barcelona. In June 2013, he was awarded a PhD Cum Laude in Medicine by the same university for his thesis on intracranial atherostenosis, supervised by Dr. Montaner Villalonga and Dr. Álvarez-Sabín. His commitment to epilepsy research led him to a Clinical and Research Fellowship in Epilepsy and EEG at Western University, Ontario, in 2014, followed by a Master in Epilepsy from the Universidad de Murcia in 2018, where he received an excellent qualification.

 Work Experience

Dr. Massot Tarrús’s medical career has spanned several prestigious institutions. Starting as a clinical observer in London (2008), he then became a Senior Neurologist in Barcelona and Madrid, working in the Neurovascular Unit at Vall d’Hebron (2009-2010) and the Epilepsy Unit at the Jiménez Díaz Foundation (2010-2011). Between 2011 and 2021, he took on various senior roles, including at Hospital del Mar and Hospital Universitario Gregorio Marañón, Madrid. Since September 2021, he has been a Senior Neurologist and Epileptologist at Hospital Universitari Mútua Terrassa, where he continues to excel in treating neurological disorders, particularly epilepsy.

 Skills 

Dr. Massot Tarrús is highly skilled in Electroencephalography (EEG) and Video-EEG monitoring. He has extensive experience in intraoperative electrocorticography, cortical stimulation mapping, and the Wada test. His expertise in cerebrovascular diseases and ultrasonography diagnostics has made him a leading lecturer at several top hospitals, including Vall d’Hebron, Hospital del Mar, and Hospital Gregorio Marañón.

Awards & Honors

He holds certifications in Electroencephalography from both the Canadian Society of Clinical Neurophysiology (2015) and the Spanish Society of Neurology (2016). He was also awarded a Cum Laude distinction for his doctoral work and has participated in advanced training like the NIH Stroke Scale Training by the National Stroke Association.

 Membership 

Dr. Massot Tarrús is an active member of the Spanish Society of Neurology and has contributed significantly to clinical neurophysiology through his memberships in various international medical bodies.

 Teaching Experience

Dr. Massot Tarrús has shared his knowledge extensively, offering lectures on epilepsy, neurovascular diseases, and ultrasonography techniques. He has taught at institutions like Jiménez Díaz Foundation, Hospital del Mar, and Western University, where his work in EEG and cerebrovascular illness has helped shape the careers of future neurologists.

 Research Focus

His research primarily focuses on epilepsy and ischemic cerebrovascular diseases. His PhD thesis, which examined markers of recurrence in intracranial atherostenosis, highlights his dedication to improving diagnostics and treatment outcomes in neurology. He continues to contribute to research on epilepsy and cerebrovascular conditions, aiming to reduce the recurrence of ischemic events in patients.

 

📖Publications : 

  • 📄 “Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program”
    Author: Massot-Tarrús, A.
    Journal: Epilepsia Open
    Year: 2023
    Volume: 8(3), pp. 918–929
  • 📊 “Risk factors for comorbid epilepsy in patients with psychogenic non-epileptic seizures. Dataset of a large cohort study”
    Author: Massot-Tarrús, A.
    Journal: Data in Brief
    Year: 2022
    Volume: 45, 108568
  • 🧠 “Roles of fMRI and Wada tests in the presurgical evaluation of language functions in temporal lobe epilepsy”
    Author: Massot-Tarrús, A.
    Journal: Frontiers in Neurology
    Year: 2022
    Volume: 13, 884730
  • 💊 “Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice”
    Co-author: Massot-Tarrús, A.
    Journal: Epilepsy and Behavior
    Year: 2022
    Volume: 134, 108836
  • 📈 “Factors associated with comorbid epilepsy in patients with psychogenic nonepileptic seizures: A large cohort study”
    Author: Massot-Tarrús, A.
    Journal: Epilepsy and Behavior
    Year: 2022
    Volume: 134, 108780
  • 🧩 “Cortical myoclonus associated with coeliac disease showing a characteristic EEG pattern: A case report”
    Author: Massot-Tarrús, A.
    Journal: Seizure
    Year: 2022
    Volume: 95, pp. 81–83
  • 🚑 “Response to anakinra in new-onset refractory status epilepticus: A clinical case”
    Author: Massot-Tarrús, A.
    Journal: Seizure
    Year: 2022
    Volume: 94, pp. 92–94
  • 🦠 “Neurological complications of COVID-19 in hospitalized patients: The registry of a neurology department in the first wave of the pandemic”
    Co-author: Massot-Tarrús, A.
    Journal: European Journal of Neurology
    Year: 2021
    Volume: 28(10), pp. 3339–3347
  • 📉 “Predicting outcome of patients with psychogenic nonepileptic seizures after diagnosis in an epilepsy monitoring unit”
    Author: Massot-Tarrús, A.
    Journal: Epilepsy and Behavior
    Year: 2021
    Volume: 120, 108004
  • 🧬 “E200K familial Creutzfeldt-Jakob disease. MRI, EEG, PET and neuropathological correlation in a family”
    Co-author: Massot-Tarrús, A.
    Journal: Neurologia
    Year: 2021
    Volume: 36(5), pp. 399–401

 

Hussein Al-Hakeim | Neuroscience | Best Researcher Award

Posted on by sciencefather

Prof Hussein Al-Hakeim | Neuroscience | Best Researcher Award 🏆

Peofessor of Medical Biochemistry at University of Kufa, Iraq🎓

 Professor Dr. Hussein Kadhem Al-Hakeim is a distinguished Iraqi academic specializing in Medical Biochemistry, Biological Psychiatry, Insulin Resistance, and Nanobiochemistry. Residing at 28 Al-Adala, Najaf, Iraq, he is currently affiliated with Kufa University. Dr. Al-Hakeim is well-recognized for his significant contributions to biochemistry and clinical chemistry in Iraq.

Professional Profile 

Education🎓

Dr. Al-Hakeim earned his B.Sc. in Chemistry from the University of Mosul in 1991, followed by an M.Sc. in Medical Chemistry and a High Graduate Diploma in Clinical Biochemistry from Al-Nahrain University in 2000 and 2001, respectively. He completed his Ph.D. in Medical Chemistry at the same institution in 2004. Additionally, he holds a Diploma in International Law and Diplomatic Relations from Cairo Regional Center for Training and Arbitration, obtained in 2017.

 💼Work Experience

Dr. Al-Hakeim has held various leadership roles, including Head of the Department of Chemistry at Kufa University and the University of Karbala. He has served as the Assistant Dean and Chief of the Examination Committee at the College of Science, University of Karbala. His teaching career includes extensive experience as a lecturer in postgraduate studies across multiple universities in Iraq.

 🛠️Skills

Dr. Al-Hakeim is an expert in Medical and Clinical Biochemistry, Nanobiochemistry, Insulin Resistance, and Stem Cell Technology. He has a profound knowledge of biostatistics, biosensors, and protein-nanoparticle interactions, and is skilled in advanced laboratory techniques and various biochemical analysis methods.

 🏆Awards and Honors

Dr. Al-Hakeim’s work has been recognized at numerous scientific congresses and conferences worldwide. His research contributions and academic leadership have earned him a prominent place in Iraq’s scientific community.

 Membership 🏛️and Affiliations 🤝

Dr. Al-Hakeim is an active member of several scientific committees and associations. He frequently participates in international conferences and has presented his research at numerous prestigious events.

 Teaching Experience👨‍🏫

Dr. Al-Hakeim has taught a wide range of courses at the B.Sc., M.Sc., and Ph.D. levels. His subjects include Advanced Biochemistry, Clinical Biochemistry, Toxicology, Endocrinology, Biostatistics, and more. He has also coordinated several courses and training programs, contributing significantly to the academic development of his students.

 Research Focus 🔬

Dr. Al-Hakeim’s research interests encompass Medical Biochemistry, Clinical Chemistry, Insulin Resistance Mechanisms, Stem Cell Technology, Nanobiochemistry, and the Medical Applications of Surface Chemistry. His work is particularly focused on protein-nanoparticle interactions, a field where he has made substantial contributions.

📖Publications : 

  • IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation
    • 🗓️ Year: 2015
    • 📚 Journal: Journal of Affective Disorders
  • Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses, and inflammation: a proof of concept
    • 🗓️ Year: 2023
    • 📚 Journal: Molecular Psychiatry
  • Study of the effect of iron overload on the function of endocrine glands in male thalassemia patients
    • 🗓️ Year: 2011
    • 📚 Journal: Asian Journal of Transfusion Science
  • Intersections between pneumonia, lowered oxygen saturation percentage, and immune activation mediate depression, anxiety, and chronic fatigue syndrome-like symptoms due to COVID
    • 🗓️ Year: 2021
    • 📚 Journal: Journal of Affective Disorders
  • The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments
    • 🗓️ Year: 2022
    • 📚 Journal: Molecular Psychiatry
  • The tryptophan catabolite or kynurenine pathway in COVID-19 and critical COVID-19: a systematic review and meta-analysis
    • 🗓️ Year: 2022
    • 📚 Journal: medRxiv
  • Serum levels of lipids, calcium, and magnesium in women with hypothyroidism and cardiovascular diseases
    • 🗓️ Year: 2009
    • 📚 Journal: Journal of Laboratory Physicians
  • High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and…
    • 🗓️ Year: 2020
    • 📚 Journal: Schizophrenia Bulletin
  • IL-10 is associated with increased mu-opioid receptor levels in major depressive disorder
    • 🗓️ Year: 2019
    • 📚 Journal: European Psychiatry
  • Lowered oxygen saturation and increased body temperature in acute COVID-19 largely predict chronic fatigue syndrome and affective symptoms due to Long COVID: A precision…
    • 🗓️ Year: 2023
    • 📚 Journal: Acta Neuropsychiatrica
  • The physio-affective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated with…
    • 🗓️ Year: 2023
    • 📚 Journal: Journal of Affective Disorders
  • Serum interleukin levels and insulin resistance in major depressive disorder
    • 🗓️ Year: 2018
    • 📚 Journal: CNS & Neurological Disorders – Drug Targets
  • Lowered quality of life in long COVID is predicted by affective symptoms, chronic fatigue syndrome, inflammation, and neuroimmunotoxic pathways
    • 🗓️ Year: 2022
    • 📚 Journal: International Journal of Environmental Research and Public Health
  • Schizophrenia phenomenology revisited: positive and negative symptoms are strongly related reflective manifestations of an underlying single trait indicating overall severity…
    • 🗓️ Year: 2020
    • 📚 Journal: CNS Spectrums
  • The tryptophan catabolite or kynurenine pathway in major depressive and bipolar disorder: A systematic review and meta-analysis
    • 🗓️ Year: 2022
    • 📚 Journal: Brain, Behavior, & Immunity – Health
  • The neuroimmune and neurotoxic fingerprint of major neurocognitive psychosis or deficit schizophrenia: a supervised machine learning study
    • 🗓️ Year: 2020
    • 📚 Journal: Neurotoxicity Research
  • Serum apelin and galectin-3 in preeclampsia in Iraq
    • 🗓️ Year: 2020
    • 📚 Journal: Hypertension in Pregnancy
  • Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia
    • 🗓️ Year: 2020
    • 📚 Journal: Current Topics in Medicinal Chemistry
  • Estimation of Serum Copper, Manganese, Selenium, and Zinc in Hypothyroidism Patients
    • 🗓️ Year: 2009
    • 📚 Journal: IUFS Journal of Biology
  • Major depression in children with transfusion-dependent thalassemia is strongly associated with the combined effects of blood transfusion rate, iron overload, and increased pro…
    • 🗓️ Year: 2020
    • 📚 Journal: Neurotoxicity Research

Hilmar Bading | Neuroscience | Best Researcher Award

Posted on by sciencefather

Prof Dr Hilmar Bading | Neuroscience | Best Researcher Award 

 Professor and Head of Department at Heidelberg University, Germany

 

Professor Dr. Hilmar Bading is a distinguished neurobiologist currently serving as a Professor and Chair of the Department of Neurobiology at Heidelberg University, Germany. He is also the Director of the Interdisciplinary Center for Neurosciences (IZN) at the same institution.

professional profile 

scopus

🎓 Education

Professor Bading completed his medical degree at Heidelberg University in 1984. He earned his doctorate (Dr. med.) under the supervision of Professor Wilhelm Hasselbach, with a focus on calcium transport ATPase in muscle at the Max-Planck-Institut für medizinische Forschung, Heidelberg.

💼 Work Experience

Professor Bading has an extensive academic and research career. He has held key positions including Group Leader at the MRC Laboratory of Molecular Biology in Cambridge, England (1993-2001), and postdoctoral fellowships at Harvard Medical School, USA, and the Max-Planck-Institut für molekulare Genetik, Berlin. Since 2001, he has led the Department of Neurobiology at Heidelberg University. Additionally, he is the scientific founder of FundaMental Pharma GmbH and the founder of the Hilmar Bading Stiftung BrainAid.

🔬 Research Focus

His research primarily revolves around the molecular mechanisms that regulate gene expression in neurons, particularly focusing on the role of nuclear calcium in neuroprotection and neurodegeneration. His groundbreaking work has significantly advanced our understanding of how synaptic activity influences gene expression in the nervous system.

🏆 Awards and Honors

Professor Bading’s contributions to science have been widely recognized. He has received several prestigious awards, including the Wolfgang-Paul-Prize from the Alexander von Humboldt-Foundation (2001), an ERC Advanced Grant (2008), and an ERC Proof-of-Concept Grant (2015). In 2019, he was elected as a member of the Leopoldina, the German National Academy of Sciences.

🏅 Memberships

He has been an active member of several prominent scientific boards and commissions, including the Scientific Advisory Board of the Spemann Graduate School of Biology and Medicine at the University of Freiburg, the Commission of the International Max-Planck Research Schools, and the Wellcome Trust Neuroscience Panel in London.

👨‍🏫 Teaching Experience

With a commitment to nurturing the next generation of scientists, Professor Bading has supervised over 25 PhD students as the principal supervisor and co-supervised an additional 50 PhD students. His dedication to teaching is also reflected in his guidance of approximately 80 Master’s and Bachelor’s theses over the past decade.

🔍 Skills

Professor Bading’s expertise lies in molecular biology, neurobiology, and the study of intracellular signaling pathways. His leadership in academia and industry highlights his ability to translate scientific discoveries into practical applications.

publications

  • Neuron–astrocyte metabolic coupling facilitates spinal plasticity and maintenance of inflammatory pain
    • Year: 2024
    • Journal: Nature Metabolism
    • Authors: Marty-Lombardi, S., Lu, S., Ambroziak, W., Fleming, T., Siemens, J.
    • Emoji: 🧠🔬💡
  • TwinF interface inhibitor FP802 stops loss of motor neurons and mitigates disease progression in a mouse model of ALS
    • Year: 2024
    • Journal: Cell Reports Medicine
    • Authors: Yan, J., Wang, Y.M., Hellwig, A., Bading, H.
    • Emoji: 🦠🧬🔬
  • Activin A targets extrasynaptic NMDA receptors to ameliorate neuronal and behavioral deficits in a mouse model of Huntington disease
    • Year: 2023
    • Journal: Neurobiology of Disease
    • Authors: Nassrallah, W.B., Ramandi, D., Cheng, J., Bading, H., Raymond, L.A.
    • Emoji: 🧠💉🧩
  • The Disruption of NMDAR/TRPM4 Death Signaling with TwinF Interface Inhibitors: A New Pharmacological Principle for Neuroprotection
    • Year: 2023
    • Journal: Pharmaceuticals
    • Authors: Yan, J., Bading, H.
    • Emoji: 💊🧬🔒
  • Expression of the primate-specific LINC00473 RNA in mouse neurons promotes excitability and CREB-regulated transcription
    • Year: 2023
    • Journal: Journal of Biological Chemistry
    • Authors: Pruunsild, P., Bengtson, C.P., Loss, I., Lohrer, B., Bading, H.
    • Emoji: 🧬🧠📈
  • Ryanodine Receptor Mediated Calcium Release Contributes to Ferroptosis Induced in Primary Hippocampal Neurons by GPX4 Inhibition
    • Year: 2023
    • Journal: Antioxidants
    • Authors: Gleitze, S., Ramírez, O.A., Vega-Vásquez, I., Paula-Lima, A., Hidalgo, C.
    • Emoji: 🧪🧬💥
  • Neuronal nuclear calcium signaling suppression of microglial reactivity is mediated by osteoprotegerin after traumatic brain injury
    • Year: 2022
    • Journal: Journal of Neuroinflammation
    • Authors: Fröhlich, A., Olde Heuvel, F., Rehman, R., Bading, H., Roselli, F.
    • Emoji: 🧠⚕️🔧
  • N-methyl-D-aspartate Receptor-mediated Preconditioning Mitigates Excitotoxicity in Human Induced Pluripotent Stem Cell-derived Brain Organoids
    • Year: 2022
    • Journal: Neuroscience
    • Authors: Bauersachs, H.G., Bengtson, C.P., Weiss, U., Pruunsild, P., Bading, H.
    • Emoji: 🧪🧠🌱
  • Dysregulation of Npas4 and Inhba expression and an altered excitation-inhibition balance are associated with cognitive deficits in DBA/2 mice
    • Year: 2022
    • Journal: Learning and Memory
    • Authors: Oberländer, K., Witte, V., Mallien, A.S., Bengtson, C.P., Bading, H.
    • Emoji: 🧠🧩📉
  • Disrupted expression of mitochondrial NCLX sensitizes neuroglial networks to excitotoxic stimuli and renders synaptic activity toxic
    • Year: 2022
    • Journal: Journal of Biological Chemistry
    • Authors: Hagenston, A.M., Yan, J., Bas-Orth, C., Sekler, I., Bading, H.
    • Emoji: 🧬⚠️🧠

 

Marjan Shariatpanahi | Neuroscience | Best Researcher Award

Posted on by sciencefather

Dr Marjan Shariatpanahi |  Neuroscience | Best Researcher Award 

Associate professor at Iran university of medical sciences,Iran

Dr. Marjan Shariatpanahi is an Associate Professor in the Department of Pharmacology and Toxicology at the School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran. With extensive experience in toxicology and pharmacology, Dr. Shariatpanahi has made significant contributions to research on neurodegenerative diseases and toxicology.

professional profile

scopus

google scholar

Education 🎓

Dr. Shariatpanahi holds a Doctor of Pharmacy (Pharm. D.) from Islamic Azad University, Tehran (2000-2006) with a thesis on thymidine phosphorylase and estrogen receptor alpha in colorectal cancer. She also earned a Ph.D. in Toxicology from Tehran University of Medical Sciences (2009-2014), focusing on the effects of PKG on spatial memory deficits and markers of autophagy and apoptosis in rats.

Work Experience 🏥

Dr. Shariatpanahi has a diverse professional background. She has been the Head of the Pharmacology & Toxicology Department at Iran University of Medical Sciences since 2017. Her previous roles include Dean of the Educational Office (2020-2023), Head of Student and Cultural Affairs (2019-2020), and faculty member at the Neuroscience Research Center (2018-present). She has also worked as an Assistant Professor at both Iran University of Medical Sciences and Guilan University of Medical Sciences, and as a Responsible Pharmacist in various institutions.

Skills 🛠️

Dr. Shariatpanahi is proficient in various research techniques, including IHC, Western blot, ICC, in vivo studies, and behavioral tests for neurodegenerative diseases. Her expertise extends to TLC, spectrophotometry, SPSS, PRISM, ELISA, and gas chromatography. She is also skilled in using atomic absorption machines and Endnote.

Awards and Honors 🏅

Dr. Shariatpanahi has received several accolades, including being named the best professor at the Vosough Festival of IUMS (2023) and being recognized as a selected pharmacist (2022). She was also acknowledged as a top student in toxicology and pharmacy, receiving first ranks in board examinations and seminars.

Professional Memberships 🔗

Dr. Shariatpanahi is a member of the Iranian Association of Toxicology, the Iranian Medical Council, the Iranian Association of Pharmacists, the Iranian Probiotics Society, and the Talent Society of Tehran University.

Teaching Experience 📚

Dr. Shariatpanahi has taught a wide range of courses across various levels. For Ph.D. students, she covers basics of pharmacology. For Doctor of Pharmacy students, she teaches toxicology, pharmacology, clinical toxicology, and specialized pharmacy language. Her M.Sc. teaching includes environmental toxicology, forensic toxicology, and advanced research methods, while for B.Sc. students, she focuses on toxicology.

Research Focus 🔬

Dr. Shariatpanahi’s research interests include neuroscience, with a focus on autism, Alzheimer’s disease, memory, and Parkinson’s disease. She is also involved in toxicology, environmental toxicology, pharmacology, cell signaling, stem cell therapy, and the study of behavioral investigations on animals. Her work explores various markers and mechanisms in carcinogenesis, angiogenesis, and the protective and toxic effects of nanoparticles.

Conclusion

Dr. Marjan Shariatpanahi’s extensive qualifications, leadership roles, significant research contributions, and recognition in the field make him an excellent candidate for the Best Researcher Award. His achievements demonstrate a strong commitment to advancing knowledge in pharmacology and toxicology, contributing valuable insights into neurodegenerative diseases, toxicology, and pharmacology.

publication 

 

Lianyan Huang | Neuroscience | Best Researcher Award

Posted on by sciencefather

 Prof Lianyan Huang | Neuroscience | Best Researcher Award

professor / Ph.D. advisor at Sun-yat sen university Guangzhou, China

Dr. Lianyan Huang is a professor at Zhongshan School of Medicine, Sun Yat-sen University, with expertise in neuroscience. She completed her postdoctoral training at NYU and has received numerous honors, including the Guangdong Provincial Award. Her research focuses on neural coding mechanisms and neurological disorders, with key findings published in top journals. 🧠📚🏆

professional profile :

Awards and Honors

10th SCBA Meeting Scholarship (2004) 🏅Excellent Postgraduate Scholarships of Guangdong Province (2006, 2009) 🎓Academician Scholarship of Southern Medical University (2006) 🏆Guangdong Provincial Award for Outstanding Young and Middle-Aged Clinical Medical Teachers (2023) 🏆

Professional Work Experience

Professor and Ph.D. Advisor, Zhongshan School of Medicine, Sun Yat-sen University (2017-present) 👩‍🏫Postdoctoral Fellow, NYU School of Medicine (2012-2017) 🧠Faculty and Lecturer, Southern Medical University (2008-2011) 👩‍🏫Graduate Research Assistant, The First Military Medical University (2003-2006) 👩‍🔬

Skills

Neuroscience Research 🧠Clinical Medicine 🩺Cell Biology 🔬Teaching and Advising 🎓Leadership in Professional Committees 👩‍🏫

Other Experience and Professional Memberships

  • 2006-present: Member, Society for Neuroscience of China 🧠🔬

publication:

Pain experience reduces social avoidance to others in pain: a c-Fos-based functional connectivity network study in mice

📅 2024 📰 Cerebral Cortex 🧠

Authors: Li, J., Qin, Y., Zhong, Z., Huang, L., Li, B.

Sexually dimorphic control of affective state processing and empathic behaviors

📅 2024 📰 Neuron 🧠

Authors: Fang, S., Luo, Z., Wei, Z., Huang, L., Li, B.

An insular cortical circuit required for itch sensation and aversion

📅 2024 📰 Current Biology 🧬

Authors: Zheng, J., Zhang, X.M., Tang, W., Huang, L., Li, B.

EF1α-associated protein complexes affect dendritic spine plasticity by regulating microglial phagocytosis in Fmr1 knock-out mice

📅 2024 📰 Molecular Psychiatry 🧠

Authors: Su, P., Yan, S., Chen, K., Yang, G., Liu, F.

Differences in the neural basis and transcriptomic patterns in acute and persistent pain-related anxiety-like behaviors

📅 2023 📰 Frontiers in Molecular Neuroscience 🧬

Authors: Fang, S., Qin, Y., Yang, S., Li, B., Huang, L.

Distinct behavioral traits and associated brain regions in mouse models for obsessive–compulsive disorder

📅 2021 📰 Behavioral and Brain Functions 🧠

Authors: Chen, X., Yue, J., Luo, Y., Li, B., Wen, S.

Enriched Environment Prevents Surgery-Induced Persistent Neural Inhibition and Cognitive Dysfunction

📅 2021 📰 Frontiers in Aging Neuroscience 🧬

Authors: Yang, S., Zhang, S., Tang, W., Huang, L., Li, B.

BDNF produced by cerebral microglia promotes cortical plasticity and pain hypersensitivity after peripheral nerve injury

📅 2021 📰 PLoS Biology 🔬

Authors: Huangi, L., Jin, J., Chen, K., Gan, W.-B., Yang, G.

Learning-dependent dendritic spine plasticity is impaired in spontaneous autoimmune encephalomyelitis

📅 2021 📰 Developmental Neurobiology 🧠

Authors: Huang, L., Lafaille, J.J., Yang, G.

Learning-Dependent Dendritic Spine Plasticity Is Reduced in the Aged Mouse Cortex

📅 2020 📰 Frontiers in Neural Circuits 🧬

Authors: Huang, L., Zhou, H., Chen, K., Chen, X., Yang, G.